Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive troriluzole in obsessive-compulsive disorder
2020-004653-69Phase 3Completed
- Sponsor
- Biohaven Ltd.
- Start
- Jun 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obsessive compulsive disorder (OCD) comparing Adjunctive troriluzole with Adjunctive placebo (2 arms). Primary endpoint: Change from baseline in Yale-Brown Obsessive Compulsive Scale total score. Started Jun 2021; status: completed.
02
Drugs
troriluzole
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on 2020-004653-69.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004653-69.